AARTIDRUGS Aarti Drugs Q2 FY26 results (Jul–Sep 2025) and concall
Aarti Drugs reported a strong Q2 FY26, with consolidated revenue growing 9% YoY to ₹652.9 crores, primarily driven by robust export demand. Profitability saw significant improvement, with EBITDA up 23% YoY to ₹84.4 crores and PAT increasing 29% YoY to ₹45.2 crores, leading to notable margin expansion. The new Sayakha manufacturing facility commenced operations, contributing to backward integration and raw material security. The company aims for 15-20% growth in FY27 and targets 15% EBITDA margins by H2 FY27, contingent on successful project ramp-ups.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 9.2%, net profit up 28.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 598 | 557 | 677 | 591 | 653 +9% |
| EBITDA | 67 | 62 | 93 | 74 | 84 +25% |
| Net profit | 35 | 37 | 63 | 54 | 45 +29% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
